
Mohit Narang, MD
Advertisement
Articles by Mohit Narang, MD


Switching patients with chronic lymphocytic leukemia (CLL) from ibrutinib to zanubrutinib has led to fewer cardiac adverse effects and a reduced workload for Mohit Narang, MD, managing partner at Maryland Oncology Hematology.

Mohit Narang, MD, explains why he switches patients with chronic lymphocytic leukemia (CLL) to the second-generation Bruton tyrosine kinase inhibitor.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Withdrawal of Aid Could Cause Millions of Lives Lost to HIV
2
EASO Recommends Semaglutide, Tirzepatide for First-Line Obesity Therapy
3
Recent FDA Approvals Expand Dermatology Options for Patients With Skin of Color
4
Mortality Gap Between Puerto Rico and the US Mainland Among Medicare Advantage Enrollees
5